TY - JOUR T1 - Restarting after COVID-19: A Data-driven Evaluation of Opening Scenarios JF - medRxiv DO - 10.1101/2020.05.28.20115980 SP - 2020.05.28.20115980 AU - Ashwin Aravindakshan AU - Jörn Boehnke AU - Ehsan Gholami AU - Ashutosh Nayak Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/30/2020.05.28.20115980.abstract N2 - To contain the COVID-19 pandemic, several governments introduced strict Non-Pharmaceutical Interventions (NPI) that restricted movement, public gatherings, national and international travel, and shut down large parts of the economy. Yet, the impact of the enforcement and subsequent loosening of these policies on the spread of COVID-19 is not well understood. Accordingly, we measure the impact of NPI on mitigating disease spread by exploiting the spatio-temporal variations in policy measures across the 16 states of Germany. This quasi-experiment identifies each policy’s effect on reducing disease spread. We adapt the SEIR (Susceptible-Exposed-Infected-Recovered) model for disease propagation to include data on daily confirmed cases, intra- and inter-state movement, and social distancing. By combining the model with measures of policy contributions on mobility reduction, we forecast scenarios for relaxing various types of NPIs. Our model finds that, in Germany, policies that mandated contact restrictions (e.g., movement in public space limited to two persons or people co-living), initial business closures (e.g., restaurant closures), stay-at-home orders (e.g., prohibition of non-essential trips), non-essential services (e.g., florists, museums) and retail outlet closures led to the sharpest drops in movement within and across states. Contact restrictions were the most effective at lowering infection rates, while border closures had only minimal effects at mitigating the spread of the disease, even though cross-border travel might have played a role in seeding the disease in the population. We believe that a deeper understanding of the policy effects on mitigating the spread of COVID-19 allows a more accurate forecast of the disease spread when NPIs are (partially) loosened, and thus also better informs policymakers towards making appropriate decisions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request ER -